The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo

The phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) signaling axis has emerged as a novel target for cancer therapy. Agents that inhibit PI3K, mTOR or both are currently under development. The mTOR allosteric inhibitor, RAD001, and the PI3K/mTOR dual kinase inhibitor, BEZ235, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Cheng-Xiong, Li, Yikun, Yue, Ping, Owonikoko, Taofeek K., Ramalingam, Suresh S., Khuri, Fadlo R., Sun, Shi-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114848/
https://www.ncbi.nlm.nih.gov/pubmed/21695126
http://dx.doi.org/10.1371/journal.pone.0020899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114848/
https://www.ncbi.nlm.nih.gov/pubmed/21695126
http://dx.doi.org/10.1371/journal.pone.0020899

Ejemplares similares